Dirk Klingbiel

5.6k total citations · 2 hit papers
86 papers, 3.8k citations indexed

About

Dirk Klingbiel is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dirk Klingbiel has authored 86 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 30 papers in Pathology and Forensic Medicine and 30 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dirk Klingbiel's work include Colorectal Cancer Treatments and Studies (21 papers), Genetic factors in colorectal cancer (15 papers) and HER2/EGFR in Cancer Research (12 papers). Dirk Klingbiel is often cited by papers focused on Colorectal Cancer Treatments and Studies (21 papers), Genetic factors in colorectal cancer (15 papers) and HER2/EGFR in Cancer Research (12 papers). Dirk Klingbiel collaborates with scholars based in Switzerland, Italy and United States. Dirk Klingbiel's co-authors include Fred T. Bosman, Sabine Tejpar, Mauro Delorenzi, Roberto Fiocca, Roberto Labianca, A. Roth, Eric Van Cutsem, David Cunningham, Laura A. Cisar and Bernard Nordlinger and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Dirk Klingbiel

85 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

2009 893 citations Arnaud Roth, Sabine Tejpar et al. profile →
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features

2014 477 citations Edoardo Missiaglia, Bart Jacobs et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Dirk Klingbiel

Since Specialization

Citations

This map shows the geographic impact of Dirk Klingbiel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Klingbiel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Klingbiel more than expected).

Fields of papers citing papers by Dirk Klingbiel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Klingbiel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Klingbiel. The network helps show where Dirk Klingbiel may publish in the future.

Co-authorship network of co-authors of Dirk Klingbiel

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Klingbiel. A scholar is included among the top collaborators of Dirk Klingbiel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Klingbiel. Dirk Klingbiel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis 2023 ·Clinical Cancer Research ·Grazia Arpino, Juan de la Haba-Rodríguez, Jean-Marc Ferrero, Sabino De Placido, C. Kent Osborne, Dirk Klingbiel, (unknown), (unknown), (unknown), Mothaffar F. Rimawi, (unknown)	25
2	288P Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) 2020 ·Annals of Oncology ·D.W. Miles, Eva Ciruelos, Andreas Schneeweiß, Fabio Puglisi, (unknown), Mario Campone, Igor Bondarenko, Zbigniew Nowecki, Hassan Errihani, Shani Paluch–Shimon, Andrew Wardley, (unknown), (unknown), Dirk Klingbiel, (unknown), Thomas Bachelot	2
3	Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort 2019 ·Scientific Reports ·Zsuzsanna Varga, Qiyu Li, Wolfram Jochum, (unknown), Tilman T. Rau, (unknown), Hanne Hawle, Dirk Klingbiel, Beat Thuerlimann, Thomas Ruhstaller	10
4	Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data 2019 ·BMC Cancer ·Sabine Schmid, Dirk Klingbiel, Stefan Aebi, Aron Goldhirsch, Christoph Mamot, Elisabetta Munzone, Franco Nolè, C. Oehlschlegel, Olivia Pagani, Bernhard C. Pestalozzi, Christoph Rochlitz, Beat Thürlimann, Roger von Moos, Patrik Weder, Khalil Zaman, Thomas Ruhstaller	7
5	Vitamin D levels in Swiss breast cancer survivors 2018 ·Swiss Medical Weekly ·Michaël Baumann, Sérgio U. Dani, Daniel Dietrich, (unknown), Dirk Klingbiel, Michael Mark, Walter F. Riesen, Thomas Ruhstaller, Arnoud J. Templeton, Beat Thürlimann	5
6	Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08) 2017 ·European Journal of Cancer ·Roger von Moos, Dieter Koeberle, (unknown), Stefanie Hayoz, (unknown), Arnaud Roth, G. Bodoky, Panagiotis Samaras, Martin D. Berger, Daniel Rauch, Piercarlo Saletti, Ludwig Plaßwilm, Daniel R. Zwahlen, Urs R. Meier, (unknown), Paola Izzo, Dirk Klingbiel, Daniela Bärtschi, Kathrin Zaugg	20
7	Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort 2017 ·Journal of Hematology & Oncology ·Darius Juškevičius, (unknown), Dirk Klingbiel, Christoph Mamot, Stephan Dirnhofer, Alexandar Tzankov	60
8	Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer 2016 ·Clinical Cancer Research ·Pu Yan, Dirk Klingbiel, Zenia Saridaki, Paola Ceppa, Monica Curto, Thomas McKee, Arnaud Roth, Sabine Tejpar, Mauro Delorenzi, Fred T. Bosman, Roberto Fiocca	62
9	A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing 2016 ·Journal of Thoracic Oncology ·Klazien Matter‐Walstra, Matthias Schwenkglenks, Stefan Aebi, Konstantin J. Dedes, Joachim Diebold, (unknown), Dirk Klingbiel, Roger von Moos, Oliver Gautschi	70
10	Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs) 2016 ·Journal of Thoracic Oncology ·Sabine Schmid, Oliver Gautschi, Sacha I. Rothschild, Michael Mark, Patrizia Froesch, Dirk Klingbiel, Hermann Reichegger, Wolfram Jochum, Joachim Diebold, Martin Früh	55
11	Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non–Small Cell Lung Cancer Patients (SAKK 19/05 trial) 2015 ·Clinical Cancer Research ·(unknown), Florent Baty, (unknown), Oliver Dürr, (unknown), Daniel Betticher, Bogdan Grigoriu, Dirk Klingbiel, Francesco Zappa, Martin Brutsche	8
12	Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience 2015 ·Annals of Oncology ·(unknown), Richard Cathomas, Matthew Wheater, Dirk Klingbiel, Martin Fehr, (unknown), Hannah Markham, (unknown), Simon J. Crabb, T. Geldart	26
13	Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis 2015 ·International Journal of Radiation OncologyBiologyPhysics ·Niloy R. Datta, Emsad Puric, Dirk Klingbiel, Silvia Gómez, Stephan Bodis	159
14	Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience 2015 ·Supportive Care in Cancer ·(unknown), Richard Cathomas, Michael Mark, Roger von Moos, Dirk Klingbiel, Peter Brossart, Ulrich Mey	8
15	Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features breakdown → 2014 ·Annals of Oncology ·Edoardo Missiaglia, Bart Jacobs, (unknown), Antonio Fabio Di Narzo, Charlotte Soneson, Eva Budínská, Vlad Popovici, Loredana Vecchione, Sarah Gerster, Ping Yan, A. Roth, Dirk Klingbiel, Fred T. Bosman, Mauro Delorenzi, Sabine Tejpar	477
16	Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial 2014 ·Annals of Oncology ·Dirk Klingbiel, Zacharenia Saridaki, A. Roth, Fred T. Bosman, Mauro Delorenzi, Sabine Tejpar	168
17	Delivery of health care at the end of life in cancer patients of four swiss cantons: a retrospective database study (SAKK 89/09) 2014 ·BMC Cancer ·Klazien Matter‐Walstra, Rita Achermann, Roland Rapold, Dirk Klingbiel, Andrea Bordoni, Silvia Dehler, Gernot Jundt, Isabelle Konzelmann, Kerri M. Clough‐Gorr, Thomas D. Szucs, Matthias Schwenkglenks, Bernhard C. Pestalozzi	15
18	Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer 2013 ·Supportive Care in Cancer ·Felicitas Hitz, Karin Ribi, Qiyu Li, Dirk Klingbiel, Thomas Cerny, Dieter Koeberle	21
19	Molecular and clinical determinants of survival following relapse after treatment of stage ii-iii colon cancer (cc). results of the translational study on the petacc 3-eortc 40993-sakk 60-00 trial 2010 ·Annals of Oncology ·A. Roth, Dirk Klingbiel, Ping Yan, Roberto Fiocca, Mauro Delorenzi, Roberto Labianca, David Cunningham, Eric Van Cutsem, Fred T. Bosman, Sabine Tejpar	2
20	Molecular markers in colon cancer have a stage specific prognostic value. results of the translational study on the petacc 3-eortc 40883-sakk 60-00 trial 2009 ·Annals of Oncology ·A. Roth, Sabine Tejpar, Ping Yan, Roberto Fiocca, Dirk Klingbiel, Mauro Delorenzi, Damien Dietrich, Roberto Labianca, David Cunningham, Eric Van Cutsem, Fred T. Bosman	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact